Synthesis, chemical, electrochemical characterization of oxomolybdenum(V) complexes of 2-(3,5-dimethyl pyrazol-1-yl) benzothiazole ligand: Crystal structure of ligand and oxomolybdenum(VI) complex and density functional theory (DFT) calculation

Anti-cancer property and DNA binding interaction of first row transition metal complexes: A decade update

Metal ions carry out a wide variety of functions, including acid-base/redox catalysis, structural functions, signaling, and electron transport. Understanding the interactions of transition metal complexes with biomacromolecules is essential for biology, medicinal chemistry, and the production of synthetic metalloenzymes. After the coincidental discovery of cisplatin, importance of the metal complexes in biochemistry became a top priority for inquiry. In this review, a decade update on various synthetic strategies to first row transition metal complex and their interaction with DNA through non-covalent binding are explored. Moreover, this effort provides an excellent analysis on the efficacy of theoretical and practical approaches to the systematic generation of new non-platinum based metallodrugs for anti-cancer therapeutics.

Synthesis, X-ray structure, physicochemical properties and anticancer activity of mer and fac Ru(iii) triphenylphosphine complexes with a benzothiazole derivative as a co-ligand

Two mononuclear ruthenium(iii) mer- and fac-isomers of the formula [RuCl3(PPh3)(dmpbt)] (where PPh3 = triphenylphosphine, dmpbt = 2-(3,5-dimethylpyrazoll-yl)benzothiazole) have been synthesised from the reaction of [RuCl3(PPh3)3] with a bidentate ligand - dmpbt. Appropriate reaction conditions allowed obtaining the two isomers separately without separation techniques. X-ray crystallography has determined the crystal and molecular structures of the new complexes. mer-Ru(iii) (1) crystallised in the monoclinic P2(1)/n group, and fac-Ru(iii) (2, 2') in the triclinic P1[combining macron] space group. The composition of the ruthenium coordination sphere was confirmed and characterised using spectroscopic techniques (FT-IR, UV-vis and EPR), elemental analysis and mass spectrometry (MS-FAB). The structures of the complexes obtained were analysed using X-ray and other spectroscopic methods (IR and UV-vis). The electrochemical properties of the ligand and the complex compound were identified using cyclic voltammetry, determining the potential and charge of faradaic processes. Both isomers are redox active and display quasi-reversible metal centered redox processes for the Ru(iii)/Ru(ii) pair. Moreover, preliminary tests of their biological activity were performed. The cytotoxicity of these compounds has been tested for human lung carcinoma (A549), chronic myelogenous leukemia (K562), human cervix carcinoma (HeLa) cells, acute lymphoblastic leukemia (MOLT-4), human breast adenocarcinoma cell line (MCF-7) and normal human umbilical vein endothelial cells (HUVEC). The ability to induce apoptosis has been demonstrated in caspase 3/7 activity assay. In addition, the lipophilicity of both isomers was described by a partition coefficient, log P, values of which were estimated by the shake-flask method. The interesting and promising preliminary results of the biological and chemical activities of the new octahedral mer/fac Ru(iii) complexes motivate further in vitro and in vivo studies.

New mononuclear and binuclear oxomolybdenum(V) complexes containing NN chelator: Syntheses, DFT calculations, interaction with BSA protein and in vitro cytotoxic activity

A neutral bidentate ligand 2-(3-methyl-5-phenyl pyrazol-1-yl) benzthiazole (L) has been synthesized by refluxing equimolar proportions of 2-hydrazino benzthiazole and benzoyl acetone in ethanol. The ligand acts in a NN donor fashion and forms stable mononuclear, MoOX₃L [L = Ligand, X = Cl (1), Br (2)] and binuclear Mo₂O₄X₂L₂ [L = Ligand, X = Cl (3), Br (4)] complexes with molybdenum(V). The ligand and complexes are thoroughly characterized by elemental analyses, IR, UV-Vis spectroscopy, EPR study, magnetic susceptibility, thermogravimetry and cyclic voltammetry. Magnetic moment measurements reveal that the mononuclear complexes are paramagnetic while the binuclear complexes are diamagnetic in nature. EPR studies also confirm the presence of a mononuclear Mo(V) moiety in the complexes. Relevant Density Functional Theory (DFT) calculations have been carried out to determine the structures of the synthesized compounds. The binding mode and mechanism of interaction of the synthesized compounds with bovine serum albumin (BSA) were studied by concentration dependent absorption and fluorescence titration experiments. The ligand and complexes 1-4 are screened for their potential in vitro anticancer activities against three different human cancer cell lines, namely, cervix adenocarcinoma epithelial cells (HeLa), renal carcinoma cells (SK-RC-45) and breast adenocarcinoma cells (MCF-7). The oxomolybdenum(V) complexes are found to exhibit higher anticancer potency towards the cancer cells than the free ligand. Also, structure activity relationship (SAR) studies of this new series of oxomolybdenum(V) complexes indicate that the anticancer activity is to some extent dependent on the electronic effects of the halogen atom coordinated to the molybdenum centre.